Eli Lilly is the clear frontrunner to be the largest pharmaceutical stock in 2034. See what its prospects are for the next ...

Time spent above, not below, the target glucose range was associated with mortality in a study of adults with type 2 diabetes ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 586.36% and ...

Eli Lilly stock may look expensive, but that may not be the case in a few years as the business grows at a rapid pace.

This is thanks to Lilly's dominance in the billion-dollar weight loss drug market. Lilly's Mounjaro and Zepbound have helped ...

A majority of the employers that are coming to the career fair usually are recruiting for full-time opportunities, but I ...

There is soaring demand for weight-loss drugs in the GLP-1 class, and the company will now sell it to certain professions for ...

Shares of Eli Lilly & Co. LLY sank 0.13% to $904.97 Wednesday, on what proved to be an all-around poor trading session for ...

Two new papers by a team of researchers at Boston University, the Indiana University School of Medicine and the Alzheimer’s Disease Neuroimaging Initiative (ADNI), and the German Center for ...

Drugmaker Eli Lilly on Wednesday urged a federal appeals court to overturn a $183 million judgment against it in a case ...

Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...